Connective Tissue Disease Associated with Interstitial Lung Disease (CTD ILD) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment (Broad spectrum antibiotics, Immunosuppressants, Corticosteroids, Others), By Route of Administration (Oral, Parenteral, Others), By Dosage Form (Tablets, Capsules, Injections, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), and Region Forecast 2020-2031

Connective Tissue Disease Associated with Interstitial Lung Disease (CTD ILD) Market size was valued at US$ X million in 2024 and is projected to reach at US$ X million in 2031 growing at a CAGR X% from 2025-2031. Connective Tissue Disease Associated with Interstitial Lung Disease (CTD ILD) is a complex and debilitating condition that involves inflammation and scarring of the lung tissue due to an underlying connective tissue disorder. This condition is characterized by the involvement of various connective tissue diseases, such as rheumatoid arthritis, systemic sclerosis, dermatomyositis, and systemic lupus erythematosus. CTD ILD can lead to significant impairment in lung function, causing symptoms like shortness of breath, cough, and fatigue, ultimately impacting the patient's quality of life. The prevalence of CTD ILD varies depending on the specific connective tissue disease involved.

According to data the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), approximately 15% to 20% of patients with connective tissue diseases develop interstitial lung disease. For instance, around 30% of patients with systemic sclerosis are affected by ILD, while 10% to 30% of rheumatoid arthritis patients may also develop this complication. Furthermore, studies have shown that CTD ILD is more common in females and tends to occur in individuals over the age of 50. The impact of CTD ILD on patients' lives and healthcare systems is substantial. It significantly increases morbidity and mortality rates among those affected. Patients with CTD ILD often require hospitalizations and frequent medical interventions, leading to an increased burden on healthcare resources. Moreover, the disease can be challenging to diagnose accurately due to overlapping symptoms with other lung conditions, leading to delayed treatment and potential complications. Treatment for CTD ILD usually involves a multidisciplinary approach, including immunosuppressive medications, anti-inflammatory drugs, and supportive care to manage symptoms and improve lung function. However, the effectiveness of treatment can vary depending on the specific connective tissue disease involved and the stage of lung involvement at the time of diagnosis.

Key Developments

• In March 2022, Boehringer Ingelheim received an FDA grant for the expanded indication of its Ofev (Intedanib) for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
• In February 2023, GSK announced that FDA has granted Orphan Drug Designation (ODD) to Benlysta (Belimumab) for systemic sclerosis (SSc), a rare autoimmune disease that can affect multiple organs.